1. Introduction {#s1}
===============

The usefulness of cardiac resynchronization therapy (CRT) in patients with heart failure (HF) is well established.[@b1] Unfortunately, approximately one-third of the patients fail to respond to CRT, which adversely affects the utility and cost-effectiveness of this therapy.[@b2] Given its invasive nature and up-front expense, more powerful baseline predictors need to be developed to identify patients most likely to benefit from CRT.

The metabolites present reflect the biochemical reactions that have taken place in the body, and changes in metabolites occur in response to biological events and reflect the real-time pathophysiological state. Therefore, it is possible to identify biomarkers of biological events by focusing on the changes in metabolites, and provide a predictive platform for relevant early warning signals. Through metabolomics, we can quantitatively analyze metabolites in living organisms, explore the relationship between metabolites and pathophysiological changes, and further correlate these results with the clinical phenotype of diseases.[@b3]--[@b5]

The serum-based metabolic profiling method has recently emerged as a powerful analytical tool for the identification of disease-related biomarkers and pathways that can be used to develop new diagnostic and treatment methods.[@b6] Therefore, the purpose of this prospective study was to explore the abnormal metabolic profile in HF patients, and then to evaluate their relevance as markers for CRT response.

2. Methods {#s2}
==========

2.1. Study population {#s2a}
---------------------

Twenty-five consecutive HF patients who were scheduled to undergo CRT were prospectively enrolled in this study from January 2018 to May 2018. The indication and class of recommendation for CRT as per the 2016 European Society of Cardiology (ESC) guidelines[@b7] were as follows: symptomatic HF patients with a QRS duration ≥ 130 ms and left ventricular ejection fraction (LVEF) ≤ 35%, in NYHA functional class II-IV despite optimal medical treatment. Patients were excluded from the study for the following reasons: narrow QRS, right bundle branch block (RBBB), a history of cardiac surgery, previous acute myocardial infarction, and absence of clinical follow-up. Left bundle branch block (LBBB) was diagnosed according to the criteria proposed by the 2013 ESC guidelines[@b8] of the Class 1 recommendation for CRT, namely, a wide QRS duration with QS or rS in V1, broad (frequently notched or slurred) R wave in leads I, aVL, V5, or V6, and absence of q waves in leads V5 and V6. Intraventricular conduction delay was diagnosed as non-specific QRS morphology that did not fit the criteria for LBBB and RBBB.[@b9] Ten healthy controls matched for age and sex, who came to our hospital for a health check-up, without documented cardiovascular diseases and history of cardiovascular medication, and with normal cardiac function, were selected for the study.

This study was approved by the medical ethics committee of our hospital and written informed consent was obtained from all the subjects who participated in this study.

2.2. Baseline and follow-up evaluation {#s2b}
--------------------------------------

All HF patients underwent baseline and 6-month follow-up evaluations. The clinical characteristics were obtained from the electronic medical record. Electrocardiographic assessment including calculation of the QRS duration and determination of the morphological characteristics of the waves was also conducted. The premature ventricular contraction (PVC) burden was documented from a 24-h period of Holter monitoring within one week. Patients who had \> 10,000 PVC in a 24-h period were offered radiofrequency ablation of the PVC after they were informed of the benefits and risks of the procedure and following their consent for the procedure. Transthoracic echocardiography was performed according to the American Society of Echocardiography guidelines:[@b10],[@b11] left ventricular end-diastolic volume (LVEDV), left ventricular end-systolic volume (LVESV), and LVEF measured by using biplane Simpson\'s method. Septal-posterior wall motion delay (SPWMD), i.e., the time delay between the septum and posterior wall transiting from an inward to outward motion, was measured by color tissue Doppler M-mode from the parasternal short-axis view. Interventricular mechanical delay (IVMD), which is defined as the difference between left ventricular (LV) and right ventricular (RV) pre-ejection intervals, was measured as the time from the onset of QRS to the onset of LV ejection versus RV ejection in the LV and RV outflow tracts, respectively. The Yu index was determined as the standard deviation of time from QRS to peak systolic velocity in the ejection phase for 12 LV segments (6 basal and 6 middle) from three standard apical views in tissue Doppler imaging. According to the findings of clinical and echocardiographic assessments at the 6 month follow-up, patients were allocated to two groups: (1) responders (patients with decreases in NYHA class ≥ one grade and a reduction of LVESV ≥ 15%);[@b12],[@b13] and (2) non-responders (patients with no improvement in the results of clinical and echocardiographic assessments or who were re-hospitalized or underwent cardiac transplantation or died for or with worsening HF at follow-up after CRT implantation).[@b14]

2.3. Metabolomics analysis {#s2c}
--------------------------

### 2.3.1. Collection of blood samples {#s2c1}

Peripheral venous and coronary sinus blood samples were collected from HF patients at the time of CRT implantation. Peripheral venous blood samples were also obtained from 10 healthy controls who had visited the hospital for a health check-up. Each whole-blood sample was centrifuged at 4°C at 3000 r/min. for 15 min. Aliquots of 500 µL were finally transferred to cryovials, frozen, and stored at −80°C until metabolomics analysis.

Frozen serum samples were thawed on ice and vortexed thoroughly. Four hundred microliters of methanol/acetonitrile (1: 1, v/v, prechilled to −20°C) solvent was added to 100 µL serum. The mixture was vortexed for 30 s and then incubated for 30 min at −20°C. Subsequently, the mixture was centrifuged at 12,000 r/min for 15 min at 4°C. The supernatant (400 µL) was collected and divided into 200 µL and 100 µL aliquots, and then dried under vacuum. The residues were reconstituted for analysis using hydrophilic interaction liquid chromatography (HILIC) and reversed-phase liquid chromatography (RPLC) coupled to mass spectrometry, respectively. The LC-MS/MS analysis conducted is detailed in the Supplementary Material. Quality control (QC) samples were prepared by mixing equal volumes (20 µL) of each serum sample. The QC sample was periodically injected with batches of 10 test samples throughout the analytical run.

### 2.3.2. Data processing and analysis {#s2c2}

The raw data were acquired using the software Xcalibur (version 3.1, Thermo Scientific) and then converted to mzXML files with MSConvert of ProteoWizard (version 3.0). The peak identification, peak filtration, peak alignment, and isotope annotation were performed using the XCMS program (version 3.0.0) with CAMERA (version 1.34.0) in R package version 3.4.3 to obtain the data matrix containing mass-to-charge (m/z), retention time, integrated peak intensity, and isotope annotation.

Each dataset was imported into SIMCA (V13.0, Umetrics, Umeå, Sweden) for further analysis. Principal component analysis and partial least squares discriminant analysis (PLS-DA) were performed to visualize the metabolic alterations between different groups after mean centering and unit variance scaling. Cross-validation was carried out to prevent overfitting (The validation graphs were presented as [Figure 1S](#s0g1){ref-type="supplementary-material"} and the model quality parameters presented in [Table 1S](#s0t1){ref-type="supplementary-material"}[](#jgc-16-07-529-t04){ref-type="table"} were in the Supplementary Material). Student\'s *t*-test was used to determine the statistical significance of the variables between the two groups. Metabolites of variable importance of projection (VIP) \> 1 and *P* value \< 0.05 were identified as differential metabolites between the two groups. The significant metabolites were identified by MS/MS fragment analysis with databases such as mzCloud, HMDB (<http://hmdb.ca>), and lipidmaps (<http://www.lipidmaps.org>). MetaboAnalyst 4.0 and MBROLE 2.0 were used to identify a variety of functional enrichment analysis and metabolic pathways.

2.4. Model construction for the prediction of CRT response {#s2d}
----------------------------------------------------------

Binary logistic regression analyses were employed to construct the models for prediction. Significant variables selected in univariate analysis (*P* \< 0.05) were entered into the multivariate logistic regression analysis. The model of prediction accuracy assessment was conducted by constructing a receiver operating characteristic (ROC) curve. Probability values were yielded from the prediction models, which were subsequently utilized as new input variables for the ROC curve analysis. The optimal cut-off value, which combined the higher value of specificity plus sensitivity, was identified from the ROC curve. A two-sided *P* value \< 0.05 was accepted as indicating statistical significance.

2.5. Statistical methods {#s2e}
------------------------

Clinical and echocardiographic characteristics were expressed as the mean ± SD for continuous variables and as the number (percent) for categorical variables. Continuous variables of two groups were compared using the Student\'s *t*-test (for normally distributed) and Wilcoxon test (for non-normally distributed). Categorical variables were compared by the Chi-squared test or Fisher\'s exact test as appropriate. Correlations between two variables were analyzed using Pearson\'s correlation test. All data were analyzed using SPSS version 24.0 (SPSS Inc, Chicago, IL, USA).

3. Results {#s3}
==========

In this study, 10 healthy subjects (61.8 ± 8.8 years, 25% female, 74.3 ± 9.5 beats/min) and 25 HF patients scheduled for CRT (60.3 ± 11.9 years, 20% female, 75.6 ± 16.3 beats/min) were included as the control and test groups, respectively. At the 6-month follow-up, 17 (68%) of the 25 HF patients were classified as responders, while 8 patients (32%) were classified as non-responders. Clinical and echocardiographic characteristics of CRT responders versus non-responders are summarized in [Table 1](#jgc-16-07-529-t01){ref-type="table"}. No significant differences were observed in the baseline variables between the two groups, while at the 6-month follow-up, the responders showed a significant improvement in NYHA class and echocardiographic findings compared to the non-responders.

###### Clinical and echocardiographic characteristics of CRT responders versus non-responders at baseline and 6-month follow-up.

  Variable                             Responders (*n* = 17)   Non-responders (*n* = 8)     *P*
  ----------------------------------- ----------------------- -------------------------- ----------
  Baseline                                                                               
   Age, yrs                                 65.9 ± 7.0               58.3 ± 13.7           0.172
   Female gender                              4 (24%)                  1 (13%)             0.915
   Heart rate, beats/min                    71.9 ± 14.1              74.7 ± 18.5          0\. 735
   SBP, mmHg                               120.9 ± 32.5              110.9 ± 10.5          0.444
   DBP, mmHg                                72.6 ± 8.7                71.6 ± 8.7           0.879
  QRS                                                                                    
   Duration, ms                            161.1 ± 22.5              138.9 ± 25.9          0.057
   LBBB morphology                           10 (59%)                  5 (63%)             0.861
   NYHA functional class                     2.8 ± 0.6                3.4 ± 0.7            0.068
  Class of recommendation for CRT                                                        
   I/A                                       12 (71%)                  5 (63%)             0.686
   I/B                                        3 (18%)                  2 (25%)             0.668
  Coronary artery disease                     4 (24%)                  4 (50%)             0.388
  Hypertension                                9 (53%)                  2 (25%)             0.378
  Diabetes                                    4 (24%)                  1 (13%)             0.915
  Renal insufficiency                         2 (12%)                  1 (13%)             0.958
  Atrial fibrillation                         6 (35%)                  3 (38%)             0.915
  PVC burden in a 24-h period                                                            
   \< 1000                                    9 (53%)                  4 (50%)             0.891
   1000--10,000                               6 (35%)                  3 (38%)             0.915
   \> 10,000                                  2 (12%)                  1 (13%)             0.958
  Serum biomarkers                                                                       
   CK-MB, U/L                               10.9 ± 4.2                11.8 ± 3.7          0\. 566
   CK-MM, U/L                              55.3 ± 28.13              58.7 ± 30.9           0.798
   Cre, µmol/L                              82.4 ± 41.0              88.2 ± 17.8           0.565
   hs CRP, mg/L                             7.9 ± 12.6                6.2 ± 9.2            0.930
   Uric acid, µmol/L                       472.4 ± 135.8            499.3 ± 178.2          0.643
   NT-proBNP, pg/mL                       3541.5 ± 3389.1          3537.6 ± 2849.2        0\. 998
   cTnT, ng/mL                             0.019 ± 0.010            0.023 ± 0.020          0.107
  Medication                                                                             
   ACEI/ARBs                                 10 (59%)                  5 (63%)             0.861
   Beta-blockers                              8 (47%)                  3 (38%)             0.986
   Diuretics and/or spironolactone            8 (47%)                  3 (38%)             0.986
   Antiarrhythmics                           11 (65%)                  5 (63%)             0.915
   Mitral regurgitation \> grade II           7 (41%)                  4 (50%)             0.678
   LVEDV, mL                               222.9 ± 92.9             268.6 ± 171.7          0.392
   LVESV, mL                               161.1 ± 75.2             195.0 ± 129.7          0.414
   LVEF, %                                  28.0 ± 6.6                28.6 ± 5.3           0.817
   SPWMD, ms                                177 ± 82.2               124.9 ± 48.2          0.052
   IVMD, ms                                 46.2 ± 35.4              37.6 ± 33.5           0.062
   Yu index, ms                             63.7 ± 36.7              42.8 ± 20.9           0.091
  Follow-up                                                                              
   NYHA functional class                     1.8 ± 0.6                3.8 ± 0.5           \< 0.001
   LVEDV, mL                               155.5 ± 72.2             314.6 ± 121.4         \< 0.001
   LVESV, mL                                94.9 ± 54.9             249.6 ± 107.3         \< 0.001
   LVEF, %                                  41.9 ± 10.8               23.1 ± 7.7          \< 0.001
   SPWMD, ms                                93.6 ± 40.4              96.1 ± 76.1           0.900
   IVMD, ms                                 24.3 ± 27.1               21.9 ± 31            0.079
   Yu index, ms                             36.6 ± 17.8              51.3 ± 22.6           0.049

Data are expressed as *n* (%) or mean ± SD. ACEI: angiotensin converting enzyme inhibitor; ARB: angiotensin receptor blocker; CK-MB: creatine kinase MB fraction; CK-MM: creatine kinase MM fraction; Cre: creatinine; CRT: cardiac resynchronization therapy; cTnT: cardiac troponin T; DBP: diastolic blood pressure; hs CRP: high-sensitive C-reactive protein; IVMD: interventricular mechanical delay; LBBB: Left bundle branch block; LVEDV: left ventricular end-diastolic volume; LVEF: left ventricular ejection fraction; LVESV: left ventricular end-systolic volume. NT-proBNP: N-terminal of the prohormone brain natriuretic peptide; NYHA: New York Heart Association; PVC: premature ventricular contraction; SBP: systolic blood pressure; SPWMD: septal-posterior wall motion delay; Yu index: the standard deviation of time from QRS to peak systolic velocity in ejection phase for 12 LV segments.

3.1. Abnormal metabolomic profile of HF patients {#s3a}
------------------------------------------------

The PLS-DA score plots showed a clear separation in the peripheral venous blood under four modes between the HF patients and healthy controls ([Figure 1A](#jgc-16-07-529-g001){ref-type="fig"}). Differential metabolites that met the selection criteria of VIP \> 1 and *P* value \< 0.05 are listed in [Table 2S](#s0t2){ref-type="supplementary-material"} in the Supplementary Material. These metabolites were selected to be analyzed further for their possible roles in the pathogenesis of HF. Metabolic pathways most affected in HF, as deduced from an altered serum metabolomic profile, are shown in [Figure 2A](#jgc-16-07-529-g002){ref-type="fig"}.

![PLS-DA score plots between two groups under four modes.\
(A): Peripheral venous blood from HF patients and healthy controls; (B): peripheral venous blood from CRT responders and non-responders; and (C): coronary sinus blood from CRT responders and non-responders. The data points (A) representing the HF patient group were shown to be clustered together and separated from those of the control group in both the PLS-DA score plots constructed for HILIC/ESI+, HILIC/ESI−, RPLC/ESI+ and RPLC/ESI− mode. Similarly, the metabolic profiles of peripheral venous blood (B) and coronary sinus blood (C) from CRT responders exhibited a pattern distinct from non-responders under four modes, which characterized by changes in the levels of certain serum metabolites (see [Table 2](#jgc-16-07-529-t02){ref-type="table"}). The validation graphs of [Figure 1](#jgc-16-07-529-g001){ref-type="fig"} PLS-DA score plots were presented as [Figure 1S](#s0g1){ref-type="supplementary-material"} and the detailed model quality parameters were presented in [Table 1S](#s0t1){ref-type="supplementary-material"} in the Supplementary Materials. CRT: cardiac resynchronization therapy; HF: heart failure; PLS-DA: partial least squares discriminant analysis.](jgc-16-07-529-g001){#jgc-16-07-529-g001}

![Metabolic pathways as deduced from differential metabolites of peripheral venous blood between HF patients and healthy subjects (A), as well as between CRT responders and non-responders (B).\
All matched pathways are plotted according to *P* values from pathway enrichment analysis and pathway impact values from pathway topology analysis. Color gradient and circle size indicate the significance of the pathway ranked by p value (yellow: higher *P* values and red: lower *P* values) and pathway impact values (the larger the circle the higher the impact score). Only the significantly affected pathways with low *P* value and high pathway impact score are shown. CRT: cardiac resynchronization therapy; HF: heart failure.](jgc-16-07-529-g002){#jgc-16-07-529-g002}

3.2. Differential metabolites between CRT responders and non-responders {#s3b}
-----------------------------------------------------------------------

The PLS-DA score plots showed a clear separation in the peripheral venous blood under four modes between CRT responders and non-responders ([Figure 1B](#jgc-16-07-529-g001){ref-type="fig"}). Differential metabolites that met the selection criteria of VIP \> 1 and P value \< 0.05 are listed in [Table 2](#jgc-16-07-529-t02){ref-type="table"}. These metabolites were selected to be analyzed further for their clinical implications in the potential mechanism underlying the response to CRT. The most affected metabolic pathways, as deduced from differential metabolites, are shown in [Figure 2B](#jgc-16-07-529-g002){ref-type="fig"}.

###### Differential metabolites between CRT responders and non-responders.

  HMDB ID                                              Compound name                         *P*-value    VIP    Fold Change
  ----------------------------- ----------------------------------------------------------- ----------- ------- -------------
  **Peripheral venous blood**                                                                                   
   HILIC/ESI+ mode                                                                                              
    HMDB0003905                                  Imidazole-4-acetaldehyde                    1.67E-02    1.728      1.48
    HMDB0000214                                          Ornithine                           1.81E-02    2.096      1.91
    HMDB0000517                                         L-arginine                           5.61E-03    2.072      1.37
    HMDB0000670                                       Homo-L-arginine                        3.03E-03    2.329      1.73
    HMDB0005015                                N6, N6, N6-Trimethyl-L-lysine                 1.29E-02    1.729      1.55
    HMDB0038662                               N-(1-Deoxy-1-fructosyl) alanine                4.93E-02    1.312      1.56
    HMDB0037842                               N-(1-Deoxy-1-fructosyl) serine                 2.01E-02    1.485      1.66
    HMDB0028965                                    Lysyl-Gamma-glutamate                     4.36E-03    1.904      2.53
    HMDB0037840                               N-(1-Deoxy-1-fructosyl) leucine                1.55E-02    1.609      1.63
    HMDB0002089                                     N-Ribosylhistidine                       2.48E-02    1.809      1.68
    HMDB0037845                              N-(1-Deoxy-1-fructosyl) tyrosine                8.78E-03    1.680      1.70
   HILIC/ESI− mode                                                                                              
    HMDB0000251                                           Taurine                            2.28E-03    2.259      1.67
    HMDB0000517                                         L-arginine                           6.74E-04    2.256      1.88
    HMDB0038662                               N-(1-Deoxy-1-fructosyl) alanine                3.01E-02    1.451      1.69
    HMDB0037840                               N-(1-Deoxy-1-fructosyl) leucine                3.71E-02    1.403      1.63
    HMDB0037846                            N-(1-Deoxy-1-fructosyl) phenylalanine             1.15E-02    1.736      1.77
   RPLC/ESI+ mode                                                                                               
    HMDB0000517                                         L-arginine                           1.50E-02    1.862      1.39
    HMDB0062594                                     Methyl Arachidonate                      4.89E-02    1.462      1.78
    HMDB0010384                                        LysoPC (18:0)                         8.88E-03    1.732      1.35
   RPLC/ESI− mode                                                                                               
    HMDB0004702                                         12,13-EpOME                          4.87E-02    2.208      0.69
    HMDB0007850                                       LPA (0:0/18:0)                         1.93E-02    1.760      1.23
    HMDB0062312                  1-(5Z,8Z,11Z,14Z-eicosatetraenoyl)-sn-glycero-3-phosphate   2.35E-02    2.072      1.37
    HMDB0011130                                      LysoPE (18:0/0:0)                       2.21E-02    1.723      1.22
    HMDB0010386                                    LysoPC (18:2(9Z,12Z))                     4.84E-02    1.493      1.23
    HMDB0007075                                DG (15:0/18:3(6Z,9Z,12Z)/0:0)                 3.56E-02    1.750      1.62
  **Coronary sinus blood**                                                                                      
   HILIC/ESI+ mode                                                                                              
    HMDB0036803                                    Lysyl-Gamma-glutamate                     3.29E-02    1.972      2.08
   HILIC/ESI− mode                                                                                              
    HMDB0028965                                        Stearic acid                          2.48E-02    2.500      0.76
    HMDB0000827                                   6-O-Acetylaustroinulin                     5.89E-03    2.742      0.69
   RPLC/ESI+ mode                                                                                               
    HMDB0000517                                         L-arginine                           4.72E-02    1.588      1.37
    HMDB0030123                           (3beta,5alpha,24S)-Ergost-8(14)-en-3-ol            1.22E-02    2.184      0.89
   RPLC/ESI− mode                                                                                               
    HMDB0000827                                        Stearic acid                          3.59E-02    1.953      0.74

CRT: cardiac resynchronization therapy.

3.3. Identification of the best predictors of CRT response based on logistical regression analysis {#s3c}
--------------------------------------------------------------------------------------------------

Of all the differential metabolites observed in the peripheral venous blood between CRT responders and non-responders, only four metabolites were found to be significant in the univariate analysis (*P* \< 0.05), namely, L-arginine, Homo-L-arginine, taurine, and ornithine, suggesting that they had a potentially predictive value and could be used to generate prediction models for CRT response based on the multivariate logistical regression analysis. The predictive capacities of each individual metabolite and the different combined prediction models were assessed by ROC curve analysis and compared to each other ([Table 3](#jgc-16-07-529-t03){ref-type="table"}). The individual area under curve (AUC) values of L-arginine, Homo-L-arginine, taurine, and ornithine were calculated to be 0.875, 0.846, 0.838, and 0.801, respectively, which were lower than that of the combined prediction model involving these four metabolites, calculated to be 0.897. Further analysis showed that the combination of L-arginine and taurine had comparable prediction accuracy to the combination of the four metabolites. When having the same prediction accuracy, it is generally best to use as few metabolites as possible to construct the combined prediction model. Therefore, the optimal prediction model was that incorporating only the levels of L-arginine and taurine, which were expressed using the following equation after the raw data of concentration levels were normalized by dividing them with the 8^th^ power of 10: $$\text{Prediction~Model~(CRT-Re)} = \text{2.348} \times \text{L-arginine} + \text{4.946} \times \text{taurine} - \text{5.988}$$

ROC analysis identified the optimal cutoff value of this prediction model as 0.343 (sensitivity, 88.2%; specificity, 87.5%; AUC = 0.897, *P* = 0.002) in predicting response to CRT ([Figure 3](#jgc-16-07-529-g003){ref-type="fig"}).

###### Receiver operating characteristic analysis for predicting CRT response.

  Test variables                                        Area under the curve   *P*-value
  ---------------------------------------------------- ---------------------- -----------
  L-arginine                                                   0.875             0.003
  Homo-L-arginine                                              0.846             0.006
  Taurine                                                      0.838             0.007
  Ornithine                                                    0.801             0.017
  L-arginine + Homo-L-arginine + Taurine + Ornithine           0.897             0.002
  L-arginine + Homo-L-arginine + Taurine                       0.897             0.002
  L-arginine + Taurine                                         0.897             0.002
  L-arginine + Homo-L-arginine                                 0.882             0.002
  L-arginine + Ornithine                                       0.868             0.004

CRT: cardiac resynchronization therapy.

![ROC curve of prediction model (CRT-Re) for predicting response to CRT.\
CRT: cardiac resynchronization therapy; ROC: receiver operating characteristic.](jgc-16-07-529-g003){#jgc-16-07-529-g003}

3.4. Analysis of the origin for some metabolite biomarkers {#s3d}
----------------------------------------------------------

The PLS-DA score plots also showed a clear separation in the coronary sinus blood under four modes between CRT responders and non-responders ([Figure 1C](#jgc-16-07-529-g001){ref-type="fig"}). Differential metabolites that met the selection criteria of VIP \> 1 and *P* value \< 0.05 are listed in [Table 2](#jgc-16-07-529-t02){ref-type="table"}. The differential metabolites present both in peripheral venous and in coronary sinus blood were L-arginine and lysyl-gamma-glutamate. Concentrations of L-arginine and lysyl-gamma-glutamate in peripheral venous serum were significantly correlated with those in contemporaneous coronary sinus serum taken at the time of CRT implantation, suggesting a cardiac origin for L-arginine and lysyl-gamma-glutamate (*r* = 0.945 and 0.680, respectively, all *P* \< 0.001) ([Figure 2S](#s0g2){ref-type="supplementary-material"} in the Supplementary Material).

4. Discussion {#s4}
=============

The present study was designed to analyze the abnormal metabolic profiles in patients with HF, and to explore their relevance as markers for CRT response so as to provide a complementary tool for guiding selection of patients scheduled for CRT. The main findings were that (1) peripheral venous blood exhibited an abnormal metabolomic profile in patients with HF; (2) concentration of many identified metabolites was significantly different between CRT responders and non-responders at baseline, thus, we constructed a prediction model for CRT outcome using two differential metabolites; and (3) further analysis suggested the cardiac origin for some differential metabolites present in peripheral venous blood. The key metabolites were mapped to biochemical metabolic pathways ([Figure 3S](#s0g3){ref-type="supplementary-material"} in the Supplementary Material), which could show the network and interaction of the metabolic pathways being the background of metabolites investigated in this study.

4.1. Metabolic disturbances in patients with HF {#s4a}
-----------------------------------------------

Emerging metabolomic analysis permits simultaneous evaluation of multiple metabolites and metabolic pathways.[@b3],[@b4],[@b15] A comprehensive metabolomic evaluation in our study indicated that HF patients have clinically relevant disturbances in concentration of circulating metabolites, which improved the understanding of HF pathogenesis. The abnormal metabolomic profiling revealed that differential metabolites were mainly clustered in several key pathways, including fatty acid metabolism, glycerophospholipid metabolism, arginine and proline metabolism, histidine metabolism and biosynthesis of unsaturated fatty acids, which might be perturbed by the development of HF. This result also suggested the deficiency in energy production in patients with HF, because fatty acids are the primary energy source for myocardial cells and have been proposed to be associated with diagnosis and prognosis of cardiovascular diseases in many studies.[@b16],[@b17] Purine is a key component of adenosine triphosphate (ATP), therefore, a decrease in the ATP level caused by redox imbalance and deficient substrate oxidation resulted in an increase in the concentration of end-product of purine metabolism, such as urate.[@b18] This also indicated impaired oxidative metabolism, which highly correlated with disease severity of HF.[@b19],[@b20] Therefore, urate has been suggested as a marker of HF.[@b21],[@b22] Our findings are consistent with those of previous studies. On one hand, higher levels of serum urate, glutamate, proline, and urea indicated alterations in Krebs cycle, amino acid metabolism, and nucleotide degradation. On the other hand, the metabolomic profile of patients with HF also revealed lower levels of serum glycine, histidine, and serine, suggesting that mitochondrial dysfunction and energy deficiency are the significant metabolic changes in the failing heart.[@b23],[@b24] Histidine can be converted to glutamate, which enters Krebs cycle as alpha-ketoglutarate to supply energy or enters glutamate-ornithine-proline pathway to supply ornithine. A simultaneous and significant decrease in arginine levels may be associated with nitric oxide (NO) synthesis.[@b25] In addition to above-mentioned changes, the lipid metabolism was also reduced in patients with HF, which manifested as decreased serum levels of linoleate and myristate.

Other studies have also demonstrated the presence of a specific metabolomic profile in HF patients,[@b23] but these findings are not entirely consistent with the results from our HF population; this may be owing to different patients\' characteristics such as the course and severity of HF or differences in the metabolomic analysis technique used.

4.2. Metabolic biomarker for response to CRT {#s4b}
--------------------------------------------

The serum metabolic profiles of CRT responders differed from those of non-responders at baseline evaluation: responders showed higher baseline levels of important metabolites, including representative fatty acids (such as arachidonic acid), amino acids (such as arginine, taurine, and ornithine), and lipids (such as glycerol-3-phosphate), which are essential for protein synthesis and metabolic signaling.[@b26],[@b27] These metabolites may represent a better metabolic reserve and a higher potential for metabolic recovery in CRT responders; for example, the higher levels of ornithine as being representative of urea cycle and ammonia detoxification functioning in responders.

Considering that 30% patients fail to respond to CRT based on current guidelines, there has always been an urgent demand in clinical electrophysiologic research for more powerful baseline predictors to guide patient selection for CRT, such as echocardiographic parameters,[@b28] multi-parameter clinical scores,[@b25] protein[@b29],[@b30] and extracellular RNA.[@b31] Metabolomics, as a powerful screening tool, has increasingly been used for the diagnosis and prognosis of various cardiovascular diseases such as myocardial ischemia,[@b15] coronary heart disease[@b32],[@b33] and heart failure.[@b6] Predictive analytics is an emerging area in personalized medicine;[@b34],[@b35] the application of metabolomics analysis to CRT response prediction has been previously reported,[@b36],[@b37] but contradictory findings have been reported with regard to its predictive value. Therefore, a need still exists for studies to evaluate the applicability of serum-based metabolomics analysis in predicting CRT outcome and to provide as much complementary information as possible. In the present study, we constructed a prediction model using concentration levels of two differential metabolites. If this model could be validated in a larger population, metabolic profiling of peripheral venous blood would represent a step forward in HF management and patient selection for CRT. Serum-based metabolic analysis is a high-throughput assay and employs robot-assisted automation protocols, which would facilitate routine screening as a complementary method to the conventional clinical, electrocardiographic, or image-based assessment.

We also adapted the same metabolic analysis method to coronary sinus blood and observed overlap of differential metabolites between peripheral venous blood and coronary sinus blood; we further demonstrated the significant correlations of their concentration levels in peripheral venous blood with those in coronary sinus blood. This suggests the cardiac origin of some important differential metabolic biomarker and lays the elementary foundation to further explore the mechanisms behind the relationship between CRT response and differential metabolites.

4.3. Limitations of the study {#s4c}
-----------------------------

This study was performed in a single center with a relatively small sample size; future multi-center prospective clinical trials enrolling larger populations and validation groups are necessary for our results and model to be further assessed and deemed generally applicable. Moreover, the mechanisms behind the relationship between CRT response and differential metabolites are still not elucidated, and this aspect should be further explored in future work.

4.4. Conclusions {#s4d}
----------------

Our findings suggested that the development of HF induced a significant perturbation in circulating metabolites, while CRT responders showed a favorable metabolomic profile at baseline evaluation for predicting CRT outcome. A prediction model based on differential metabolites was constructed; these metabolites could thereby serve as potential biomarkers to complement current methods and enhance the predictive value of current evaluations. This differentiation may be useful for guiding patient selection and reducing the unnecessary invasive and costly CRT implantation, thus improving the effectiveness of CRT.

Supplementary Materials {#s5}
=======================

Methods {#s5a}
-------

### LC-MS and LC-MS/MS {#s5a1}

The sample analysis was performed on an Ultimate-3000 UPLC system coupled to a Q Exactive hybrid quadrupole-Orbitrap MS system (Thermo Scientific). The residues were re-suspended in platform specific solutions before injection. The untargeted metabolomic platform employed for this analysis was based on a combination of three conditions: (A) Hydrophilic interaction liquid chromatography (HILIC)-MS with ESI+/ESI− switching mode; (B) Reversed phase liquid chromatography (RPLC)-MS with ESI+ mode; and (C) RPLC-MS with ESI− mode. For HILIC-MS analysis, the obtained residue was reconstituted in 100 µL of acetonitrile/water (1:1, v/v), with 2-chloro-L-phenylalanine as internal standard. For RPLC-MS analysis, the residue was reconstituted in 100 µL of 80% methanol, with 2-chloro-L-phenylalanine, fatty acid 19:0, lysophosphatidylcholine 12:0, and phosphatidylcholine 22:0 as internal standards.

Gradient Profile for HILIC-MS Method An Acquity UPLC BEH Amide column (1.7 µm × 2.1 mm × 100 mm, Waters) with a VanGuard pre-column was used. The column temperature was set at 40°C. The mobile phases were 20 mM ammonium acetate and 20 mM ammonium hydroxide in water/acetonitrile (95:5, v:v) (A) and acetonitrile (B). The flow rate was 0.35 mL/min and the injection volume was 5 µL. The gradient was 85% B in 0--1.0 min, 85--65% B in 1.0--12.0 min, 65--40% B in 12.0--12.1 min, 40% B in 12.1--15.0 min, 40--85% B in 15.0--15.1 min, and 85% B in 15.1--20.0 min. All the samples were kept at 4°C during the analysis.

Gradient Profiles for RPLC-MS Methods A Hypersil GOLD C8 column (1.9 µm × 2.1 mm × 100 mm, Thermo Scientific) with a guard filter was used. The column temperature was set at 40°C. For ESI+ mode, the mobile phases were 0.1% formic acid in methanol (A) and 5% methanol in water with 0.1% formic acid (B). For ESI-- mode, the mobile phases were 6.5 mM ammonium bicarbonate in methanol with 5% water (A) and 6.5 mM ammonium bicarbonate in water with 5% methanol (B). For both positive and negative modes, the flow rate was 0.35 mL/min and the injection volume was 5 µL. The gradient was 100% B in 0--1.0 min, 100--0% B in 1.0-5.5 min, 0% B in 5.5--8.0 min, 0--100% B in 8.0--8.1 min, and 100% B in 8.1--12.0 min. All the samples were kept at 10°C during the analysis.

Electrospray ionization in both of the liquid condition was carried out using the following conditions. Full scan data was acquired in positive, negative, or positive/negative ion switching modes in profile mode at 70,000 resolution (at m/z range 70--1050), an automatic gain control target of 3e6, with spray voltages +3.0 kV and --2.5 kV. The capillary temperature was set at 350°C with the sheath gas flow rate at 45 arb and aux gas flow rate at 15 arb. The heater temperature was set at 350°C. The S-Lens RF level was set at 50.

The MS/MS was operated at a resolving power of 70,000 in full-scan mode (scan range: 70--1050 m/z); automatic gain control target: 1e6 both in positive and negative ion mode) and of 17,500 in the Top10 data-dependent MS2 mode (stepped normalized collision energy: 15, 30 and 45 in positive mode and 30, 45, 60 in negative ion mode; Injection time: 100 ms; Isolation window: 4.0 m/z; automatic gain control target: 2e5) with dynamic exclusion setting of 6.0 s.

###### Model quality parameters for [Figure 1](#jgc-16-07-529-g001){ref-type="fig"} PLS-DA models

  Mode                                                            R2X (cum)   R2Y (cum)   Q2Y (cum)   Intercept  
  -------------------------------------------------------------- ----------- ----------- ----------- ----------- -----------
  Peripheral venous blood of HF patients vs. healthy controls                                                    
   HILIC/ESI+                                                       0.207       0.958       0.862       0.815      --0.104
   HILIC/ESI−                                                       0.185       0.976       0.877       0.845      --0.122
   RPLC/ESI+                                                        0.187       0.972       0.789       0.853      --0.029
   RPLC/ESI−                                                       0.0944       0.883       0.747       0.663      --0.159
  Peripheral venous blood of CRT responders vs. non-responders                                                   
   HILIC/ESI+                                                       0.128       0.941      --0.207      0.906       0.127
   HILIC/ESI−                                                      0.0806       0.752      0.0412       0.685     --0.0183
   RPLC/ESI+                                                        0.128       0.969       0.224       0.967     --0.0179
   RPLC/ESI−                                                       0.0616       0.863       0.02        0.79      --0.0355
  Coronary sinus blood of CRT responders vs. non-responders                                                      
   HILIC/ESI+                                                       0.138       0.907      --0.171      0.884      0.0396
   HILIC/ESI−                                                      0.0756       0.685       --0.1       0.666     --0.00184
   RPLC/ESI+                                                        0.144       0.948      0.0478       0.946     --0.00651
   RPLC/ESI−                                                        0.142       0.965       0.208       0.957       0.316

###### Abnormal metabolomic profiling in peripheral venous blood of HF patients.

  HMDB ID                                             Compound name                                    *P* Value    VIP    Fold Change
  ----------------- --------------------------------------------------------------------------------- ----------- ------- -------------
  HILIC/ESI+ mode                                                                                                         
   HMDB0034301                                         Piperidine                                      3.75E-04    1.314      9.506
   HMDB0000112                                   Gamma-Aminobutyric acid                               9.47E-06    2.209      0.614
   HMDB0000097                                           Choline                                       3.51E-05    1.914      0.730
   HMDB0000187                                          L-Serine                                       2.59E-06    2.177      0.689
   HMDB0004437                                       Diethanolamine                                    2.11E-04    1.427      1.837
   HMDB0003905                                  Imidazole-4-acetaldehyde                               2.57E-02    1.373      0.665
   HMDB0000870                                          Histamine                                      1.26E-04    1.558      0.677
   HMDB0062558                                        pyroglutamine                                    2.18E-06    1.637      3.131
   HMDB0013704                                    6-Methylnicotinamide                                 8.85E-03    1.878      0.374
   HMDB0003464                                  4-Guanidinobutanoic acid                               7.29E-05    1.991      0.703
   HMDB0000895                                        Acetylcholine                                    2.85E-02    1.159      1.381
   HMDB0000897                                       7-Methylguanine                                   1.60E-03    1.34       1.240
   HMDB0004225                                        2-Oxoarginine                                    4.50E-04    1.762      0.681
   HMDB0000517                                         L-arginine                                      4.41E-02    1.025      0.817
   HMDB0003157                                   Guanidinosuccinic acid                                5.78E-03    1.064      2.910
   HMDB0002189                                     N8-Acetylspermidine                                 4.54E-02    1.001      1.293
   HMDB0000679                                       Homocitrulline                                    1.81E-03    1.093      2.446
   HMDB0011667                                     5-L-Glutamylglycine                                 1.13E-02    1.228      0.621
   HMDB0000684                                        L-Kynurenine                                     1.55E-03    1.220      1.311
   HMDB0003764                                       Glutamylalanine                                   3.66E-02    1.406      0.549
   HMDB0000014                                        Deoxycytidine                                    3.20E-02    1.39       0.702
   HMDB0031701                     1-(gamma-Glutamylamino)cyclopropanecarboxylic acid                  4.82E-03    1.031      1.595
   HMDB0014426                                          Lidocaine                                      4.50E-05    1.493    1199.596
   HMDB0028732                                 Asparaginyl-Hydroxyproline                              3.38E-04    1.296      6.536
   HMDB0000497                                     5,6-Dihydrouridine                                  2.34E-02    1.039      3.015
   HMDB0013133                                   Methylmalonylcarnitine                                3.02E-02    1.034      1.439
   HMDB0037842                               N-(1-Deoxy-1-fructosyl) serine                            1.45E-02    1.368      0.618
   HMDB0000133                                          Guanosine                                      2.67E-04    1.287      7.641
   HMDB0000552                                  3-Methylglutarylcarnitine                              2.36E-02    1.046      2.026
   HMDB0029119                                   Tyrosyl-Gamma-glutamate                               1.81E-03    1.428      1.716
   HMDB0000791                                     L-Octanoylcarnitine                                 1.10E-03    1.316      1.602
   HMDB0028896                                    Histidinyl-Tryptophan                                6.38E-03    2.058      0.053
  HILIC/ESI− mode                                                                                                         
   HMDB0003355                                     5-Aminovaleric acid                                 1.03E-03    1.660      0.793
   HMDB0003640                                        DL-β-Leucine                                     5.25E-06    1.862      0.705
   HMDB0000930                                     trans-Cinnamic acid                                 3.43E-05    1.990      0.671
   HMDB0003412                                         L-Histidine                                     4.12E-05    2.091      0.589
   HMDB0000543                                    4-Phenylbutyric acid                                 4.96E-06    2.772      0.072
   HMDB0000159                                       L-Phenylalanine                                   4.15E-05    1.993      0.678
   HMDB0003357                                      N-Acetylornithine                                  5.34E-05    2.662      0.097
   HMDB0000517                                         DL-arginine                                     9.51E-03    1.257      0.672
   HMDB0012326                                           Hexose                                        7.38E-04    1.202      1.348
   HMDB0061890                                     Pyroglutamylglycine                                 2.70E-03    2.198      0.166
   HMDB0000127                                      D-Glucuronic acid                                  1.29E-02    1.203      1.561
   HMDB0035484                        3-(3,4-Dihydroxy-5-methoxy)-2-propenoic acid                     2.35E-06    2.263      0.490
   HMDB0000806                                        Myristic acid                                    2.46E-02    1.648      0.478
   HMDB0031701                     1-(gamma-Glutamylamino)cyclopropanecarboxylic acid                  6.48E-04    1.992      0.505
   HMDB0003229                                      Palmitoleic acid                                   2.52E-03    1.708      0.435
   HMDB0062550                               2-methoxyacetaminophen sulfate                            8.87E-03    1.072      1.650
   HMDB0000830                                       Neuraminic acid                                   1.73E-02    1.288      0.598
   HMDB0005766                                     Norophthalmic acid                                  1.48E-02    1.579      0.570
   HMDB0000673                                        Linoleic acid                                    1.28E-03    1.527      0.576
   HMDB0001043                                      Arachidonic acid                                   3.09E-06    2.448      0.456
   HMDB0002759                                    Androsterone sulfate                                 1.24E-02    1.854      0.258
   HMDB0010320                                   Cortolone-3-glucuronide                               1.45E-03    1.248      2.002
  RPLC/ESI+ mode                                                                                                          
   HMDB0000097                                           Choline                                       1.31E-08    2.053      0.651
   HMDB0000687                                          L-Leucine                                      5.03E-04    1.526      0.787
   HMDB0000062                                         L-Carnitine                                     3.36E-03    1.058      1.688
   HMDB0000159                                       L-Phenylalanine                                   1.22E-04    1.883      0.726
   HMDB0000289                                          Uric acid                                      2.24E-04    1.776      2.369
   HMDB0000517                                         L-arginine                                      4.75E-03    1.310      0.749
   HMDB0000197                                      Indoleacetic acid                                  7.42E-03    1.144      1.522
   HMDB0000201                                     Acetyl-L-carnitine                                  1.34E-05    1.459      3.748
   HMDB0000684                                        L-Kynurenine                                     2.44E-02    1.022      1.207
   HMDB0013687                                         Nootkatone                                      6.01E-04    1.213      1.388
   HMDB0011174                                        Prolylleucine                                    6.90E-03    1.050      1.274
   HMDB0014426                                          Lidocaine                                      3.55E-04    1.301     341.937
   HMDB0013133                                   Methylmalonylcarnitine                                1.57E-04    1.508      2.507
   HMDB0029586                                       Octadecanamine                                    6.81E-03    1.208      1.057
   HMDB0013130                                      Glutarylcarnitine                                  1.52E-03    1.436      2.394
   HMDB0000706                                 L-Aspartyl-L-phenylalanine                              5.19E-07    2.225      0.272
   HMDB0037840                               N-(1-Deoxy-1-fructosyl) leucine                           1.77E-03    1.386      2.270
   HMDB0013302                                  Phenylalanylphenylalanine                              2.22E-03    1.819      0.384
   HMDB0062594                                Arachidonic acid methyl ester                            4.04E-03    1.762      0.389
   HMDB0061636                                 3-hydroxydecanoyl carnitine                             4.50E-03    1.063      2.130
   HMDB0006070                                        Pregnanetriol                                    1.11E-02    1.429      0.615
  RPLC/ESI− mode                                                                                                          
   HMDB0003355                                     5-Aminovaleric acid                                 3.33E-02    1.314      0.884
   HMDB0003640                                        DL-β-Leucine                                     1.12E-04    2.043      0.769
   HMDB0000482                                        Caprylic acid                                    2.54E-07    3.349      0.190
   HMDB0000148                                       L-Glutamic acid                                   9.72E-03    1.662      0.765
   HMDB0000847                                        Nonanoic acid                                    2.15E-02    1.029      1.328
   HMDB0000159                                       L-Phenylalanine                                   1.10E-04    2.405      0.674
   HMDB0000289                                          Uric acid                                      8.01E-04    2.201      2.138
   HMDB0000806                                        Myristic acid                                    4.17E-02    1.871      0.496
   HMDB0000826                                     Pentadecanoic acid                                  2.98E-02    1.752      0.782
   HMDB0033428                                       (+)-Setoclavine                                   3.11E-03    1.523      1.661
   HMDB0002186                                        Hypogeic acid                                    1.02E-02    1.969      0.398
   HMDB0000220                                        Palmitic acid                                    8.85E-03    1.986      0.507
   HMDB0000827                                        Stearic acid                                     3.35E-02    1.624      0.667
   HMDB0001043                                      Arachidonic acid                                   7.38E-05    2.870      0.378
   HMDB0010378                                 5,8,11-Eicosatrienoic acid                              7.99E-03    2.242      0.365
   HMDB0013302                                  Phenylalanylphenylalanine                              4.37E-03    2.239      0.379
   HMDB0059915                                4-Dodecylbenzenesulfonic acid                            1.70E-03    1.651      1.145
   HMDB0002183                                    Docosahexaenoic acid                                 1.94E-04    2.849      0.298
   HMDB0001976                                Docosapentaenoic acid (22n-6)                            1.02E-02    2.156      0.341
   HMDB0039762                        1,1′-\[1,11-Undecanediylbis(oxy)\]bisbenzene                     1.32E-03    1.296      2.351
   HMDB0014359                                         Torasemide                                      4.17E-03    1.207    4469.611
   HMDB0062319                              1-dodecanoyl-glycero-3-phosphate                           5.61E-04    1.963      1.377
   HMDB0002833                                    Testosterone sulfate                                 1.16E-07    2.998      0.398
   HMDB0002759                                    Androsterone sulfate                                 1.76E-02    1.613      0.611
   HMDB0000348                             3b,12a-Dihydroxy-5a-cholanoic acid                          5.56E-03    1.264      1.420
   HMDB0007849                                       LPA (0:0/16:0)                                    1.27E-05    2.735      0.692
   HMDB0062318                             1-heptadecanoyl-glycero-3-phosphate                         5.95E-03    2.041      0.533
   HMDB0062712                   3alpha,7beta-dihydroxy-5beta-cholest-24-en-26-oic Acid                1.82E-03    1.383      1.431
   HMDB0007856                                   LPA (18:2(9Z,12Z)/0:0)                                1.97E-04    2.244      0.669
   HMDB0007855                                     LPA (18:1(9Z)/0:0)                                  4.88E-04    2.383      0.682
   HMDB0007850                                       LPA (0:0/18:0)                                    1.83E-03    2.056      0.735
   HMDB0002126                         27-Nor-5b-cholestane-3a,7a,12a,24,25-pentol                     4.56E-02    1.139      1.272
   HMDB0029804                                          Momordol                                       5.76E-03    1.342      1.406
   HMDB0002157                                    27-Norcholestanehexol                                1.20E-02    1.394      1.359
   HMDB0062307                1-(4Z,7Z,10Z,13Z,16Z,19Z-docosahexaenoyl)-glycero-3-phosphate            2.28E-04    2.140      0.582
   HMDB0002409             N-\[(3a,5b,7b)-7-hydroxy-24-oxo-3-(sulfooxy) cholan-24-yl\]-Glycine         1.15E-02    1.126      3.019
   HMDB0002430       (3a,5b,7a)-23-Carboxy-7-hydroxy-24-norcholan-3-yl-b-D-Glucopyranosiduronic acid   2.59E-02    1.066      1.887
   HMDB0001008                                         Biliverdin                                      2.52E-02    1.287      1.432
   HMDB0002579                          Glycochenodeoxycholic acid 3-glucuronide                       1.97E-03    1.363      2.627

###### The validation graphs of [Figure 1](#jgc-16-07-529-g001){ref-type="fig"} PLS-DA score plots.

(A), (B), and (C) are the corresponding validation models of [Figure 1](#jgc-16-07-529-g001){ref-type="fig"} PLS-DA models (A), (B), and (C). A default seven-round cross-validation in SIMCA was performed throughout to determine the optimal number of principal components and to avoid model overfitting. The PLS-DA models were also validated by a permutation analysis (200 times). The quality of the models is described by the R2X or R2Yand Q2 values. R2X or R2Y is defined as the proportion of variance in the data explained by the models and indicates goodness of fit. Q2 is defined as the proportion of variance in the data predicted by the model and indicates predictability, calculated by a cross-validation procedure. All the permuted R2 (cum) and Q2 (cum) values were shown on the figures, which indicating the relatively good predictive capability and the models are valid without overfitting. The detailed model quality parameters were presented in [Table 1S](#s0t1){ref-type="supplementary-material"}.

###### 

Click here for additional data file.

###### Correlations of the concentration level in peripheral venous blood with that in coronary sinus blood.

(A): L-arginine; (B): Lysyl-gamma-glutamate.

###### 

Click here for additional data file.

###### The interaction of the metabolic pathways being the background of key metabolites investigated in this study.

α-KG: alpha-ketoglutarate; BH~4~: tetrahydrobiopterin; NO: nitric oxide.

###### 

Click here for additional data file.
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